A5018922989- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Click Chemistry and Applications
- MicroRNA in disease regulation
- Ferroptosis and cancer prognosis
- Cancer Risks and Factors
- Estrogen and related hormone effects
- Cancer-related Molecular Pathways
- Medical Imaging Techniques and Applications
- Synthesis and biological activity
- Breast Lesions and Carcinomas
Centro de Investigación Biomédica en Red de Cáncer
2018-2025
Hospital Clínico Universitario de Valencia
2016-2025
GEICAM – Spanish Breast Cancer Group
2017-2025
Centre for Biomedical Network Research on Rare Diseases
2020-2025
INCLIVA Health Research Institute
2015-2025
Universitat de València
2015-2025
Instituto de Salud Carlos III
2019-2024
Biomedical Research Institute
2013-2024
Weatherford College
2024
Medical Research Network
2023
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, role of respect to adjuvant is unclear.In prospective trial, we randomly assigned HER2-negative cancer, one three lymph nodes, and 25 or lower (scores range from 0 100, higher scores indicating...
Abstract Purpose: We report a retrospective exploratory analysis of the association research-based prediction microarray 50 (PAM50) subtype predictor with pathologic complete response (pCR) and event-free survival (EFS) in women enrolled NeOAdjuvant Herceptin (NOAH) trial. Experimental Design: Gene expression profiling was performed using RNA from formalin-fixed paraffin-embedded core biopsies 114 pretreated patients HER2-positive (HER2+) tumors randomized to receive neoadjuvant...
Abstract Immune checkpoint blockade (ICB) benefits some patients with triple-negative breast cancer, but what distinguishes responders from non-responders is unclear 1 . Because ICB targets cell–cell interactions 2 , we investigated the impact of multicellular spatial organization on response, and explored how remodels tumour microenvironment. We show that cell phenotype, activation state location are intimately linked, influence effect differ in sensitive versus resistant tumours early...
Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer.Patients were randomly assigned to first- second-line 1,000 mg/m(2) orally twice day days 1 14 of every 21-day cycle 400 mg placebo. The primary end point was progression-free survival (PFS).In total, 229...
Abstract Background: Triple negative breast cancers of high proliferation or grade are a subgroup characterized by very poor prognosis, rapid progression to metastatic stage and onset resistance chemotherapy after initial response. As whole, triple cancer (TNBC) represents specific area medical need, in which new therapeutic approaches deserve appropriate test. Retrospective data showed that subset patients have an ongoing immune response within the tumor microenvironment, PD-L1 expression...
Abstract Background Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in disease treated dual HER2-blockade without Methods A research-based PAM50 was applied 422 tumors from five II–III clinical trials (SOLTI-PAMELA, TBCRC023, TBCRC006, PER-ELISA, EGF104090). In SOLTI-PAMELA, all patients had early were...
Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling pathological complete remission (pCR) rates compared with anthracycline-based alone. A reverse sequence did not reduce activity. Nab-paclitaxel is an albumin-bound nanoparticle paclitaxel that allows for safe infusion without premedication, and its use led to significantly higher rate pCR in the GeparSepto trial.To determine whether nab-paclitaxel improves outcomes early locally...
Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that chemotherapy in a phase III trial.PEARL multicentre, randomised study which patients aromatase inhibitor (AI)-resistant MBC were included two consecutive cohorts. In cohort 1, 1 : to palbociclib exemestane or capecitabine. On discovering new evidence about...
To assess palbociclib in combination with trastuzumab or without endocrine therapy patients HER2-positive advanced breast cancer.PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had received 2-4 prior lines of anti-HER2-based regimens. Treatment consisted 200 mg daily for 2 weeks and 1 week off plus trastuzumab. The study was based on Simon two-stage design comprising three cohorts: estrogen receptor (ER)-negative (cohort A), ER-positive B1), letrozole B2). were...
The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20-60% of HER2+/HER2-E tumors do not achieve a complete response following anti-HER2 therapies. Here we evaluate gene expression data before, during and after neoadjuvant treatment with lapatinib trastuzumab in PAMELA trial cell lines. Our results reveal that dual blockade HER2-E disease induces low-proliferative Luminal A phenotype both patient's vitro models....
Background According to the "World Cancer Research Fund" and "American Institute of Research" (WCRF/AICR) one in four cancer cases could be prevented through a healthy diet, weight control physical activity. Objective To explore association between WCRF/AICR recommendations risk breast cancer. Methods During period 2006 2011 we recruited 973 incident controls from 17 Spanish Regions. We constructed score based on 9 for prevention:: 1)Maintain adequate body weight; 2)Be physically active;...
Abstract Background Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss PTEN and/or INPP4B is common. Buparlisib an orally bioavailable, pan-class I inhibitor. We evaluated safety and efficacy buparlisib in patients with metastatic cancer. Methods This was a single-arm phase 2 study enrolling Patients were treated at starting dose 100 mg daily. The primary endpoint clinical benefit, defined as confirmed complete response (CR), partial...
Abstract The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this could optimize treatment response. Here we analyzed the involvement miRNA-449 family response to doxorubicin. cell viability, cell-cycle phases, expression silico target genes proteins sensitive/resistant lines were evaluated doxorubicin after gain/loss miRNAs-449 function achieved by transient transfection. Triple patients selected for ex vivo...
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism trastuzumab orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation PI3K/AKT MAPK pathways ligand-independent manner. Genetic depletion pharmacological inhibition restored response vitro vivo. inhibitor plus achieved complete...
Abstract Purpose: In hormone receptor–positive (HR+)/HER2− metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and discover therapeutic targets reverse this resistance. Non-luminal subtype high levels of CCNE1 are candidate biomarkers in setting, but further validation needed. Experimental Design: We performed mRNA gene expression profiling correlation with progression-free survival (PFS) on 455 tumor...
Abstract Background The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts personalized clinical management and the development of innovative strategies. Tumor-infiltrating Natural Killer (TI-NK) cells can predict efficacy HER2-targeted independently from clinicopathological factors primary HER2-positive breast cancer patients. Understanding mechanism/s underlying this association would contribute optimizing patient stratification provide rationale for...